Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 846 Views
-
Last post by NHE
-
- 0 Replies
- 2515 Views
-
Last post by frodo
-
- 0 Replies
- 1196 Views
-
Last post by NHE
-
- 1 Replies
- 1163 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1496 Views
-
Last post by frodo
-
- 0 Replies
- 1787 Views
-
Last post by NHE
-
- 0 Replies
- 2276 Views
-
Last post by vesta
-
- 0 Replies
- 1873 Views
-
Last post by frodo
-
- 0 Replies
- 2540 Views
-
Last post by DIM